Robotic brace maker Myomo Q3 revenue rises on record O&P growth

MYOMO

10/11/2025 21:30

Overview

Myomo Q3 2025 revenue up 10% to $10.1 mln, helped by record U.S. and International orthotics and prosthetics (O&P) revenue

Company reiterates full-year revenue guidance of $40 mln to $42 mln

Operating expenses decreased sequentially but rose 26% yr/yr due to higher advertising and R&D

Outlook

Myomo reiterates full-year revenue guidance of $40 mln to $42 mln

Company expects cost reduction projects to improve margins by Q3 2026

Result Drivers

RECORD O&P REVENUE - Co achieved record U.S. and International orthotics and prosthetics (O&P) revenue in Q3, contributing to revenue growth

MYOCONNECT PROGRAM - New MyoConnect program aims to lower cost per pipeline add and improve pipeline quality through therapist and physician engagement

PATIENT PIPELINE GROWTH - Patient pipeline grew by 28% yr/yr with 826 new candidates added in Q3

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.09
Q3 Net Income
-$3.70 mln
Q3 Adjusted EBITDA
-$2.70 mln
Q3 Gross Margin
63.80%
Q3 Operating Expenses
$10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Press Release: ID:nBw9ps2k4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)